软组织肉瘤化疗现状及其进展
Current Status and Advance of Chemotherapy for Soft Tissue Sarcoma
DOI: 10.12677/wjcr.2012.22002, PDF, HTML, XML, 下载: 3,681  浏览: 15,758 
作者: 佘明金：武警安徽总队医院肿瘤科，合肥；陈振东*：安徽医科大学第二附属医院肿瘤科，合肥
关键词: 软组织肉瘤；化学治疗
Soft Tissue Sarcoma; Chemotherapy
摘要: 软组织肉瘤(soft tissue sarcoma，STS)是来源于间叶组织和周围神经组织的异质性明显的实体恶性肿瘤，单纯手术治疗易出现复发及转移。对于高度恶性的软组织肉瘤、晚期局部广泛浸润和(或)复发转移的软组织肉瘤，化疗已成为重要的辅助治疗手段。为进一步提高疗效，新型细胞毒药物以及分子靶向药物开始应用于临床，已显示出较好的应用前景。
Abstract: Soft tissue sarcoma is a kind of malignant tumor derived from mesenchymal tissue and Peripheral nerve tissue, simple treatment with surgery alone is prone to recurrence and metastasis. For highly malignant soft tissue sarcoma, locally advanced extensive infiltration and (or) recurrence and metastasis in soft tissue sarcoma, chemotherapy has become an important adjuvant treatment. To further enhance the efficacy, new cytotoxic and molecular targeted drugs have been used in clinical, and shown good application prospects.
文章引用：佘明金, 陈振东. 软组织肉瘤化疗现状及其进展[J]. 世界肿瘤研究, 2012, 2(2): 9-14. http://dx.doi.org/10.12677/wjcr.2012.22002

参考文献

[1] H. G. Kopp, S. Patel, B. Brücher, et al. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma. American Journal of Clinical Dermatology, 2008, 9(4): 207-217.
[2] A. I. Spira, D. S. Ettinger. The use of chemotherapy in soft- tissue sarcomas. Oncologist, 2002, 7(4): 348-359.
[3] B. Kasper, T. Gil, V. D’Hondt, et al. Novel treatment strategies for soft tissue sarcoma. Critical Reviews in Oncology Hematology, 2007, 62(1): 9-15.
[4] S. P. Balcerzak, J. Benedetti, G. R. Weiss, et al. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A southwest oncology group study. Cancer, 1995, 76(11): 2248- 2252.
[5] W. J. Köstler, T. Brodowicz, Y. Attems, et al. Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: Results of a phase II trial. Annals of Oncology, 2001, 12(9): 1281-1288.
[6] I. Judson. Randomised phase IItrial of pegylated liposomal doxoru- bicin versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma. European Journal of Cancer, 2001, 37(7): 870-877.
[7] J. T. Hartmann, F. Mayer, J. Schleicher, et al. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). Cancer, 2007, 110(4): 861-866.
[8] J. Fayette, I. R. Coquard, L. Alberti, et al. ET-743: A novel agent with activity in soft tissue sarcomas. Oncologist, 2005, 10(10): 827-832.
[9] R. M. O’Bryan, L. H. Baker, J. E. Gottlieb, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer, 1977, 39(5): 1940-1948.
[10] V. H. Bramwell, D. Anderson, M. L. Charette, et al. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database of Systems Reviews, 2003, 3: Article ID CD003293.
[11] A. Santoro, T. Tursz, H. Mouridsen, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treat- ment of advanced soft tissue sarcomas: A randomized study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. Journal of Clinical Oncol- ogy, 1995, 13(7): 1531-1533.
[12] S. Verma, J. Younus, D. Stys-Norman, et al. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Reviews, 2008, 34(4): 339-347.
[13] V. Bramwell, D. Anderson and M. Charette. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: A meta- analysis and clinical practice guideline. Sarcoma, 2000, 4(3): 103-112.
[14] P. Lorigan, J. Verweij, Z. Papai, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard- dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European organisation for research and treatment of cancer soft tissue and bone sarcoma group study. Journal of Clinical Oncology, 2007, 25(21): 3144-3150.
[15] J. Maurel, A. López-Pousa, R. de Las Peñas, et al. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: An open-label randomized phase II study of the Spanish group for research on sarcomas. Journal of Clinical Oncology, 2009, 27(11): 1893-1898.
[16] P. Dileo, J. A. Morgan, D. Zahrieh, et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: Results of a phase II trial. Cancer, 2007, 109(9): 1863-1869.
[17] V. Bramwell, M. Blackstein, K. Belanger, et al. A Phase II Study of docetaxel in chemotherapy-naïve patients with recurrent or metastatic adult soft tissue sarcoma. Sarcoma. 1998, 2(1): 29-33.
[18] R. G. Maki, J. K. Wathen, S. R. Patel, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of sarcoma alliance for research through collaboration study 002 [corrected]. Journal of Clinical Oncology, 2007, 25(19): 2755- 2763.
[19] J. Verweij, P. G. Casali, J. Zalcberg, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet, 2004, 364(9440): 1127-1134.
[20] D. R. D’Adamo, S. E.Anderson, K. Albritton, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. Journal of Clinical Oncology, 2005, 23(8): 7135-7142.
[21] B. Kasper. Standards and novel therapeutic options in the treatment of patients with soft tissue sarcoma. Reviews on Recent Clinical Trials, 2007, 2(3): 206-211.
[22] S. R. Grobmyer, R. G. Maki, G. D. Demetri, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sar- coma. Annals of Oncology, 2004, 15(11): 1667-1672.
[23] F. C. Eilber, G. Rosen, J. Eckardt, et al. Treat-ment-induced pathologic necrosis: A predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extrem- ity soft tissue sarcomas. Journal of Clinical Oncology, 2001, 19(13): 3203-3209.
[24] T. F. DeLaney, I. J. Spiro, H. D. Suit, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. International Journal of Radiation on Oncology * Biology * Physics, 2003, 56(4): 1117-1127.
[25] W. G. Kraybill, J. Harris, I. J. Spiro, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the man- agement of high-risk, high-grade, soft tissue sarcomas of the ex- tremities and body wall: Radiation therapy oncology group trial 9514. Journal of Clinical Oncology, 2006, 24(4): 619-625.
[26] M. A. Mohagheghi, S. Sadighi, J. Raafat, et al. Neoadjuvant chemotherapy with Ifosfamide, Cisplatin, Adriamycin and Mi-tomycin (IMAP) for high risk adult soft tissue sarcomas. Acta Medica Iranica, 2009, 47(2): 133-138.
[27] E. Gortzak, A. Azzarelli, J. Buesa, et al. A randomised phase II study on neo-adjuvant chemotherapy for “high-risk” adult soft- tissue sarcoma. European Journal of Cancer, 2001, 37(9): 1096- 1103.
[28] S. Steen, G. Stephenson. Current treatment of soft tissue sarcoma. Proceedings (Baylor University Medical Center), 2008, 21(4): 392-396.
[29] Sarcoma meta analysis collaboration: Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta- analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet, 1997, 350(9092): 1647-1654.
[30] P. G. Casali, P. Picci. Adjuvant chemotherapy for soft tissue sarcoma. Current Opinion in Oncology, 2005, 17(4): 361-365.
[31] A. Figueredo, V. H. Bramwell, R. Bell, et al. Adjuvant chemotherapy following complete resection of soft tissue sarcoma in adults: A clinical practice guideline. Sarcoma, 2002, 6(1): 5-18.
[32] N. Pervaiz, N. Colterjohn, F. Farrokhyar, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer, 2008, 113(3): 573-581.
[33] F. C. Eilber, M. F. Brennan, F. R. Eilber, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Annals of Surgery, 2007, 246(1): 105-113.
[34] A. Italiano, N. Penel, Y. M. Robin, et al. Neo/adjuvant chemo- therapy does not improve outcome in resected primary synovial sarcoma: A study of the French Sarcoma Group. Annals of Oncology, 2009, 20(3): 425-430.
[35] P. J. Woll, M. V. Glabbeke, P. Hohenberger, et al. Adjuvant che- motherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): Interim analysis of a randomised phase III trial. 2007 ASCO Annual Meeting Proceedings Part I. 25(18S), June 20 Supplement, 2007: 10008.
[36] F. C. Eilber, F. R. Eilber, J. Eckardt, et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Annals of Surgery, 2004, 240(4): 686-697.
[37] M. M. Zalupski, L. H. Baker. Systemic adjuvant chemotherapy for soft tissue sarcomas. Hematology/Oncology Clinics of North America, 1995, 9(4): 787-800.
[38] J. T. Hartmann, S. Patel. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs, 2005, 65(2): 167-178.
[39] R. Palumbo, S. Palmeri and M. Antimi. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Annals of Oncology, 1997, 8(11): 1159-1162.
[40] V. Karavasilis, B. M. Seddon, S. Ashley, et al. Significant clinical benefit of first-line palliative chemotherapy in advanced soft- tissue sarcoma: Retrospective analysis and identification of prog- nostic factors in 488 patients. Cancer, 2008, 112(7): 1585-1591.
[41] C. R. Rossi, M. Deraco, M. De Simone, et al. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: Clinical outcome and prognostic factors in 60 consecutive patients. Can- cer, 2004, 100(9): 1943-1950.
[42] F. J. Lejeune, D. Liénard, M. Matter, et al. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immunity, 2006, 22(6): 6.
[43] D. J. Grünhagen, J. H. de Wilt, T. L. ten Hagen, et al. Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nature Clinical Practice Oncology, 2006, 3(2): 94-103.
[44] G. Taeger, F. Grabellus, L. E. Podleska, et al. Effectiveness of regional chemotherapy with TNF-α/Melphalan in advanced soft tissue sarcoma of the extremities. International Journal of Hyperthermia, 2008, 24(4): 193-203.
[45] A. Misra, N. Mistry, R. Grimer, et al. The management of soft tissue sarcoma. Journal of Plastic, Reconstructive & Aesthetic Surgery, 2009, 62(2): 161-174.
[46] M. Verma, J. Younus, D. Stys-Norman, et al. Dose-Intensive chemotherapy with growth factor or autologous bone marrow/ stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma. Cancer, 2008, 112(6): 1197- 1205.

为你推荐